Other studies have had similar results with regards to the effect of collagen supplementation in helping to promote fullness. One study consisted of 24 healthy adults testing the satiety effects of various protein supplements. The subjects had two breakfast meals with specific types of protein in each: one meal had alpha-lactalbumin, gelatin, or gelatin + tryptophan (TRP) (Breakfast 1) and the other meal contained casein, soy, whey, or whey + glycomacropeptide (GMP) (Breakfast 2). The study found that Breakfast 1, which included gelatin (collagen), was 40% more satiating than Breakfast 2, which did not contain gelatin or collagen. Additionally, the participants who ate Breakfast 1 with gelatin ended up consuming less calories for lunch. Researchers concluded that gelatin increases satiety, which can lead to subsequent reduced energy intake, thereby promoting weight loss (2).
If you are interested in using fat loss supplements to assist in your weight loss journey but have never used peptides before, don’t worry, our clinic doctor is available to answer any of your questions. To discuss any concerns, simply email your questions to info@musclepeptides.com.au and our doctor and professional team will get back to you so you can be one step closer to starting your weight loss journey. Want to find out more information right now? Why not see if your questions have already been answered in our FAQs?
•Avoid eating/drinking anything with calories for three (3) hours either side of your injection. •Try to make all your meals throughout the day high protein, low fat and low carbohydrates (eg. meat/fish with vegetables/salad). •Have as few meals as possible during the day as periods of fasting have been shown in many studies to improve fat loss and also longevity (i.e. eating less will make you live longer).
Finally, the hexadecapeptide AOD9604 did not induce allergenic reactions when consumed over 24 weeks. Blood of patients was analyzed for the presence of anti-AOD9604 antibody formation at various times and at the end of the studies (latest time point after 24 weeks). In none of the performed studies, at no time, were anti-AOD9604 antibodies detected in serum collected from any subjects in any treatment group.

Echocardiographic measurements obtained at pre‐ and post‐bypass visits are outlined in Table 2. Due to limitations in scanning windows and poor image quality, interpretable echocardiograms were obtained in 12 of 15 patients. Transmitral E increased from 76±19 cm/s at pre‐bypass to 83±19 cm/s at the post‐bypass surgery visit while no significant increase was noted in transmitral A. The mean intra‐individual change in transmitral E was 15 cm/s, with 95% confidence interval 3 to 26 cm/s. The increases in transmitral E were significant for the effects of saline (P=0.005) and surgery (P=0.002). There was also a significant increase in the early diastolic mitral annular velocity e′ (P=0.02 for effect of surgery). However, the E/e′ ratio did not change after surgery (Table 2). Left atrial diameter showed a trend towards decrease at the post‐bypass surgery visit (P=0.3).

There were concerns regarding the number of contraindications and precautions and whether consumers would be able to interpret these appropriately without a requirement for pharmacist advice. There were concerns regarding gastro-intestinal, renal and other adverse effects related to the potential interactions of ibuprofen and paracetamol. Also raised were concerns regarding the potential for paracetamol overdose.
The effect of AOD9604 treatment on IGF-1 levels was of particular interest, since hGH administration is associated with increases in IGF-1 levels. Prolonged increases in IGF-1 may have a variety of undesirable effects, including an increase in cancer risk [22, 23]. In this study the levels of circulating IGF-1 were measured at the baseline visit and at the end of the 12-week treatment period. There was no significant change in the levels of IGF-1 in any of the treatment groups (Table 1).
Aging often comes with many undesirable effects on our bodies including increased fat, decreased muscle muscle mass and low energy.  Some of these issues can be caused by adult growth hormone deficiency.  Peptide therapies provide a healthy option to reinvigorate the natural release of growth hormone in the body and reverse the negative effects of aging.
CJC1295 is a 30 amino acid peptide, which primarily functions as a growth hormone releasing hormone analogue (mimicking the effect of GHRH). It was initially invented to treat deep fat deposits in people, because it is known that having an increase in our own growth hormone levels will target this. It stimulates production of our own growth hormone from the pituitary gland.
For example, studies have shown that people deficient in IGF-1 have an increased chance of dying from a heart attack. This is because IGF-1 prevents the death of heart cells and offers protection to heart cells when the cells are stressed, such as during a heart attack or long amount of time without oxygen. IGF-1 has a similar protective effect on brain cells.
These peptides are inhibitors of a protein called myostatin. Myostatin is secreted by muscle cells and acts to essentially block the development of new muscle fibers and, thus, the development of lean muscle mass. In fact, individuals who have mutations in the gene coding for this protein have significantly more muscle mass and enhanced strength. The administration of follastatin peptides can generate enhanced muscle mass and strength, and has been found especially useful in patients suffering from muscle-wasting diseases or who have difficulty gaining muscle.

AOD is a peptide 15 amino acids long which mimics a small portion of the growth hormone that has the fat reducing effects (increases fat metabolism). It works by mimicking the way natural growth hormone regulates fat metabolism but without the adverse effects on blood sugar and growth that is seen if unmodified growth hormone is given. It stimulates lipolysis (break down of fat) and inhibits lipogenesis (non fat food being stored in the body as fat).
Due to the similarity of AOD9604 to the C-terminus component of hGH some parameters that are associated with hGH activity have been carefully monitored in the long-term studies: 1). Oral glucose tolerance tests (OGTT) were conducted to assess the effect of treatment on glucose handling. 2). Testing for any anti-AOD9604 antibodies in blood samples of participants was conducted to investigate if oral administration of AOD9604 resulted in the generation of neutralizing antibodies. 3). Serum levels of IGF-1 were measured to confirm the hypothesis that unlike hGH, AOD9604 does not act via IGF-1 or raise IGF-1 levels.
Whilst AOD9604 is not approved by the Australian TGA, it can be legally obtained on a doctor's prescription and dispensed by a compounding pharmacy (2). This is true of many experimental substances, but it does big favours for the reputation of AOD9604, giving the impression that, like other drugs issued by the medical profession, it is an efficacious and high quality product. These reasons, when considered together, give a powerful impression that peptides are highly effective – they wouldn't ban them for no reason, would they?
Paracetamol/caffeine formulations have a long-established safety and efficacy profile over 25 years of use as an open-sale medicine in major markets around the world. The paracetamol/caffeine combination analgesic was registered as a schedule 2 product in Australia and has been marketed since 2010. Since that time no new significant issues or potential risks have been reported.
Our peptide therapies are also known as secretagogues – a substance that promotes secretion.  These amino acid chains communicate with the body to produce or release growth hormone.  The increased volume of human growth hormone produced by the pituitary gland causes an increase in the production of Insulin-Like Grow Factor-1 (IGF-1) by the liver and results in several health benefits such as:
Your level of physical activity also affects IGF-1, and heavy weight training for your legs is a particularly potent way to increase it. Some studies suggest that the effects of the popular anti-aging supplement DHEA actually arise due to this same type of increase in IGF-1 in the body that occurs with with weight training (so you choose: heavy barbell squats or a bottle of DHEA from the drugstore).
Echocardiographic measurements obtained at pre‐ and post‐bypass visits are outlined in Table 2. Due to limitations in scanning windows and poor image quality, interpretable echocardiograms were obtained in 12 of 15 patients. Transmitral E increased from 76±19 cm/s at pre‐bypass to 83±19 cm/s at the post‐bypass surgery visit while no significant increase was noted in transmitral A. The mean intra‐individual change in transmitral E was 15 cm/s, with 95% confidence interval 3 to 26 cm/s. The increases in transmitral E were significant for the effects of saline (P=0.005) and surgery (P=0.002). There was also a significant increase in the early diastolic mitral annular velocity e′ (P=0.02 for effect of surgery). However, the E/e′ ratio did not change after surgery (Table 2). Left atrial diameter showed a trend towards decrease at the post‐bypass surgery visit (P=0.3).

Idealboost is an easy-to-use on-the-go drink packet from Idealshape, the company that brought us the best-selling meal replacement shakes. Idealboost is a simple powder designed to improve weight-loss efforts by blocking hunger, accelerating fat burning, and improving overall energy. The small packets are perfect for adding a little flavor to your water bottle and keeping on top of weight loss on the go! Read More
AOD9604 and hGH appear to act in a similar manner to induce their effects on body weight regulation and adipose tissue mass in vivo. However, in vitro studies have demonstrated a number of differences suggesting that the two compounds operate via unique signaling pathways to control the regulation of theβ 3-AR. These studies suggested that AOD9604 had no interaction with the β3-AR or hGH receptors (11).
The weight lost by the 1mg group was slightly more than that achieved by the world’s largest selling prescription obesity medication in similar trials over the same period, without its troublesome side effects. The trial results also demonstrated a small but consistent improvement in cholesterol profiles, and a reduction in the number of patients with impaired glucose tolerance.
Melanotan II: A synthetic hormone, originally developed to protect against sunlight and theoretically reduce the incidence of sun cancer, Melanotan II has also be found to stimulate male erections. Anecdotally, users report weight loss when using melanotan II and there is experimental evidence to suggest that melanotan II sends signals to the brain that the body is full. Reports of harm are rare, though it has been known to break down muscle tissue. Melanotan II is not approved for therapeutic use but is widely used by the general public. At Schedule 4 in the Poisons Standard, it is not banned by name in sport, but its anabolic effects might fall under the general “similarity of mechanism” clause.
As a athlete, incorporating a growth hormone-like Ipamorelin is extremely beneficial. Not only in the development of lean muscle tissue and muscle mass, but also in the decreased recovery time you are going to experience after each workout. You can workout more, you can workout and lift harder, and you can increase your level of exertion at the gym to experience the greatest gains, as your body is going to heal much faster than it would without the growth hormone.
The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.

Osteoarthritis (OA) is a degenerative joint disease that results from articular cartilage loss induced by complex interactions of genetic, metabolic, biochemical, and biomechanical factors with secondary components of inflammation [1]. OA is the most common arthritis and a major medical problem in people aged 65 years and older [2]. Non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, exercises, corticosteroids, and hyaluronic acid injections have all been used for the conservative treatment of OA. The role of NSAIDs in OA management is controversial because of its adverse side effects, as well as side effects on the cartilage [3].

The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the delegate included: a) the risks and benefits of the use of a substance; b) the purposes for which a substance is to be used and the extent of use of a substance; c) the toxicity of a substance; d) the dosage, formulation, labelling, packaging and presentation of a substance; e) the potential for abuse of a substance; f) any other matters that the Secretary considers necessary to protect the public health.
It is also important to note that whether you are a long-time user or a first-time user of Ipamorelin, your body is going to react differently to that of the next user. Like the benefits you will experience, the side effects you are going to experience will occur differently, and at different dosage levels. So, it truly is a trial and error period you are going to go through with a test run of Ipamorelin for new users. You have to find what works for you, how your body will react, and what potential side effects are lingering ahead, in order for you to achieve the greatest results, and eventually find the proper dosage and cycle level, which is going to work the best for your body and system.
Thymosin beta 4 (Tβ4) is the predominant form of thymosin in our bodies. It has been found in high concentrations in wound tissue and certain blood cells involved in clotting, signifying its important role in the healing process. In fact, recent studies have revealed that the first gene to be upregulated after an injury is the Tβ4 gene. As the body begins the recovery process, Tβ4 aids in the creation of new vessels in the injured area, which carry blood, nutrients, and reparative substances to the site. Tβ4 also has anti-inflammatory properties, and works to decrease the amount of inflammatory substances, called cytokines. Inflammation plays a large role in many of the symptoms associated with a large number of conditions (i.e., Lyme disease, CFS, FM, autoimmune diseases, infections, etc.), making the potential impact of Tβ4 quite extensive.
Results: After a single injection of CJC 1295, there were dose dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d. The estimated half-life of CJC 1295 was 5.8–8.1 d. After multiple CJC 1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.

I have no direct personal reports on effect of the compound. There have been a few reports put out on the Internet, but I have no better ability to summarize such findings than anyone else and generally don’t go by that, except of course I do give credence when there’s a clear, large body of results. That’s not the case here, and what there is, is certainly not in the direction of this being the next wonder.
This peptide is a modified fragment of hGH which contains the portion of the molecule that is believed to be responsible for hGH’s anti-obesity effects. The peptide has been shown to increase fat burning without the increase in blood sugar and growth rate that has been seen with hGH itself. AOD 9604 has been deemed safe for chronic use by the FDA, receiving Human GRAS status in 2014. In addition to its utility as an anti-obesity peptide, AOD 9604 has been shown to have very favorable cartilage repair and regenerative properties, especially when paired with peptide BPC 157.
Acromegaly is characterized by an excessive amount of articular cartilage in joints caused by excess GH secretion [25]. The tremendously thick articular cartilage in acromegaly can be explained by the local production of IGF-1 in cartilage cells through GH receptors [9,18]. Long-term treatment with GH might induce hypertrophy of the cartilage and changes in the joint geometry because of altered subchondral bone structures. Long-term treatment with GH by local injections may also be associated with various risks, including glucose intolerance, insulin resistance, diabetes, cancer, edema, and hypertension [26–29]. AOD9604 is not an agonist with a high affinity to the GH receptor and does not stimulate the production of IGF-1. Therefore, AOD9604 may be safer than human recombinant GH for the long-term treatment of OA.
CJC 1295 can be compounded in two forms (DAC and non-DAC). Drug affinity complex (DAC) prevents enzymatic degradation thus increasing the half-life. Consequently CJC 1295-DAC can be dosed as a single weekly injection. Administration of CJC 1295-DAC provides a GHRH-like stimulation around the clock. A potential drawback when using a weekly protocol can be attributed to ineffective GHRH stimulation when the body is due for a GH spike (usually 1:00am). This is referred to as a GH-bleed and the overall result is inferior to using CJC 1295-NON-DAC daily for 5 days out of 7. Therefore using CJC 1295-NON-DAC daily (between 6-8pm) provides a more effective GH spike at 1:00am.
One submission was received, which did not support the delegate's interim decision, as available data support that the fixed dose paracetamol/caffeine combination product provides clinically meaningful efficacy over paracetamol alone; has an excellent safety profile; a very low risk of nephrotoxicity, toxicity in overdose, misuse, abuse or illicit use; and a highly favourable risk/benefit profile.
Amongst its metabolic effects, hGH can induce inhibition of lipoprotein lipase activity in adipose tissue, stimulating lipolysis in adipocytes, which results in the reduction of fat cell mass [4-7]. Moreover, a correlation has been found between adiposity and the reduced circulating levels of hGH [8]. When applied systemically, hGH reduces body fat mass and influences fat distribution [9]. Therefore, treatment with hGH should theoretically have a positive impact on obesity. However, long term treatment with hGH is associated with various health risks, including glucose intolerance and insulin resistance, diabetes, acromegaly, cancer, edema, and hypertension [10-13].
The Ketogenic Diet is designed to force your body into ketosis, which is a normal metabolic state. Typically, the body burns carbohydrates from food to function, but when you adopt a diet of low calories (and low carbohydrates) your body switches into ketosis. When your body is in a state of ketosis the body is burning fat for energy, meaning you are tapping into the body’s fat storage that is often the hardest to shift.
In order to demonstrate safety, several human studies were performed with AOD9604 (supplementary data): 1). METAOD001: A Phase I (double-blind, placebo-controlled, dose escalation) safety study with doses (ranging from 25 to 400 µg/kg AOD9604) administered intravenously to 15 healthy adult male volunteers presenting with a BMI between 24 and 30 kg/m2. A single dose of recombinant hGH (0.12 international units/kg) was administered intravenously as positive control. 2). METAOD002: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (25, 50 and 100 µg/kg AOD9604) administered intravenously to 23 healthy clinically obese males presenting with a BMI ≥ 35 kg/m2. 3). METAOD003: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (9, 27 and 54 mg AOD9604) administered orally (capsules) to 17 healthy, clinically obese males presenting with a BMI ≥ 35 kg/m2. 4). METAOD004: A Phase IIa (double-blind, placebo-controlled, dose escalation) safety study with multiple daily doses (9, 27 or 54 mg AOD9604) administered orally (capsules) for seven days in 36 healthy clinically obese males presenting with a BMI ≥ 30 kg/m2. 5). METAOD005: A Phase IIb (randomized, double-blind, placebo-controlled) study to assess the efficacy (reduction in body weight), safety and tolerability of 12 weeks treatment with daily doses (1, 5, 10, 20 or 30 mg AOD9604) administered orally (capsules) in 300 healthy, clinically obese males, and females of non-child bearing potential, with a BMI ≥ 35 kg/m2. 6). METAOD006: A Phase IIb, randomized, double-blind, placebo-controlled study to assess the efficacy (reduction in body weight), safety and tolerability of 24 weeks treatment with different doses of AOD9604 tablets (0.25 mg, 0.5 mg, 1 mg, or placebo) in 502 obese adults.
Results: After a single injection of CJC 1295, there were dose dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d. The estimated half-life of CJC 1295 was 5.8–8.1 d. After multiple CJC 1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.
The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the Committee included: a) the risks and benefits of the use of a substance; b) the purposes for which a substance is to be used and the extent of use of a substance; c) the toxicity of a substance; d) the dosage, formulation, labelling, packaging and presentation of a substance; and f) any other matters that the Secretary considers necessary to protect public health.
Our peptide therapies are also known as secretagogues – a substance that promotes secretion.  These amino acid chains communicate with the body to produce or release growth hormone.  The increased volume of human growth hormone produced by the pituitary gland causes an increase in the production of Insulin-Like Grow Factor-1 (IGF-1) by the liver and results in several health benefits such as:
Figure 5A demonstrates that chronic administration of AOD9604 or hGH has no significant effect on the weight of white adipose tissue in either WT orβ 3-KO mice. However, in brown adipose tissue, both AOD9604 and hGH significantly reduced the size of the brown adipose tissue mass in the WT mice (Fig. 5B), by 20% and 31% (P < 0.05), respectively, as was found previously in the C57BL/6J ob/ob mice (Fig. 2B). Importantly, this effect was not observed in β3-KO mice.
Up to the date of this paper, six clinical trials (three single dose studies and three multiple dose studies from which 2 were long-term studies) have been conducted with AOD9604. In none of the three acute dose-escalating studies (METAOD001 - METAOD003) were there reported any AEs related to the intake of AOD9604, withdrawals from the study caused by AOD9604 or SAEs reported. No treatment related differences were identified upon administration of AOD9604 by IV injection (25 µg - 400 µg/kg bodyweight) or orally (9 mg - 54 mg). Treatment with AOD9604 as a single dosage had no effect on physical examination, vital signs, laboratory parameters, ECG, blood glucose and IGF-1 levels, with results indistinguishable from placebo.
Collagen is also supposed to help with joint pain. Although I (luckily) don’t have chronic pain in my joints, my knees do flare up from time to time ever since I ran a half marathon a couple years ago. I also get some soreness in what feels like the bones in my legs a couple times a week, usually after a run or intense cardio session. If drinking collagen would ease this pain, then I was game.

Human Growth Hormone (hGH) is not only important for growth processes during childhood, but plays a pivotal role in lipid metabolism throughout life. It is well known that hGH is involved in the regulation of lipolysis and lipogenesis. Therefore, hGH was implicated as a good potential candidate for the treatment of obesity. However undesired side effects, such as induction of glucose intolerance and insulin resistance, diabetes, acromegaly, cancer, edema, and hypertension [10-13] rendered therapeutic doses of hGH unsuitable for long-term treatments in humans.
It is not advisable to generalize our results for the OA in a rabbit model because of the small sample size of this study. Further studies with larger sample sizes and longer follow-ups are necessary to establish the validity of our results. Moreover, the different effects caused by varying intra-articular dosages, formulations, and injection intervals need to be assessed.
AOD9604 is promoted heavily by various manufacturers as a substance that is able to burn fat and assist in the repair of muscle and cartilage. The fact that this product derives from, and claims to mimic the effects of a powerfully anabolic banned substance provides a psychological incentive to many potential users, as does the attention drawn by the AFL "peptides" scandal of early 2013 and the subsequent report by the Australian Crime Commission (1).
No growth hormone, or any supplement for that matter, is never going to equate to the same exact results for every user. So, what you experience, is not the same as the next user, and vice-versa. Further, the increase in results and how quickly you will see these results are going to differ for each user. So, make sure you understand this prior to start your dosage, to ensure you are not disappointed if you do not see each one of these benefits, on the very first day that you begin using the Ipamorelin. Also consider the fact that if you use it after food, or with a meal, results will improve. So, proper timing and proper diet and exercise regimen can greatly enhance the results you are going to realize when you are using Ipamorelin as well.
But for maintenance of adequate and natural IGF-1 and growth hormone, and to achieve that sweet spot of not becoming to pro-growth while also not becoming a weak, muscle-less noodle, that sweet spot of producing adequate insulin without producing too much, and that sweet spot of increasing cellular repair without letting cellular division get “out of control”, I have indeed been implementing three specific strategies: my IGF-1 “trilogy”.
In the 80 years, scientists have searched different peptides and more particularly GHRH to discern what part was necessary to stimulate the pituitary response. Then in testing Sermorelin as a tool for the process of anti-agingthey found that it was the famous 1-29 chain that was responsible for stimulating the endocrine gland in question. Similarly, many studies have shown that this peptide was similar to GHRH and very well tolerated by the body.
Application would result in all current OTC paracetamol/ phenylephrine products being up-scheduled to S3. Applicant’s justification for changing current combination products from exempt or S2 to S3 is on theoretical basis only, and no evidence provided of clinical risk. Pharmacokinetic study found that co-administration of paracetamol with phenylephrine increased plasma phenylephrine levels – applicant says this has potential for cardiac safety risk in susceptible patients.
In addition to reducing calories, increasing exercise, and drinking enough water – there are other things in your life you can do which can help make losing weight easier. None of these things will help you lose weight if you don’t first get your caloric intake correct, but they can provide assistance and side benefits that make you feel better in general.
Another very positive benefit of CJC1295 is its ability to promote slow wave sleep. Slow wave sleep (SWS) is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS is decreased significantly in older adults and also with people who tend to exercise later in the evening.  This peptide has a benefit to side effect ratio that exceeds all others currently being legally sold and would make a great addition to ones training regimen or post cycle therapy.

Cancer can often be a process of uncontrolled cellular division. IGF-1 is not only pro-growth in a way that could increase this cellular division, but IGF-1 also inhibits apoptosis, or programmed cell death. Hence the theory among some in the medical community that tumors could increase synthesis of IGF-1 to keep themselves alive and to encourage the spread of cancer throughout the body. This doesn’t mean that IGF-1 directly causes cancer.
Peptide Clinics is an Australian owned and operated company, based in Sydney, that specialises in providing premium peptides online, coupled with expert medical guidance in their safe and effective use. Under the supervision of our experienced hormone doctors, Peptide Clinics Australia services thousands of clients throughout Australia with great success.
×